Shared more. Cited more. Safe forever.
    • advanced search
    • submit works
    • about
    • help
    • contact us
    • login
    View Item 
    •   MOspace Home
    • University of Missouri-Columbia
    • School of Medicine (MU)
    • Department of Family and Community Medicine (MU)
    • Family Physicians Inquiries Network (MU)
    • Clinical Inquiries (MU)
    • Clinical Inquiries, 2004
    • View Item
    •   MOspace Home
    • University of Missouri-Columbia
    • School of Medicine (MU)
    • Department of Family and Community Medicine (MU)
    • Family Physicians Inquiries Network (MU)
    • Clinical Inquiries (MU)
    • Clinical Inquiries, 2004
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    advanced searchsubmit worksabouthelpcontact us

    Browse

    All of MOspaceCommunities & CollectionsDate IssuedAuthor/ContributorTitleIdentifierThesis DepartmentThesis AdvisorThesis SemesterThis CollectionDate IssuedAuthor/ContributorTitleIdentifierThesis DepartmentThesis AdvisorThesis Semester

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular AuthorsStatistics by Referrer

    What is the best way to treat patients with white-coat hypertension?

    Rao, Shobha
    Liu, Chun-Tsai
    Wilder, Laura
    View/Open
    [PDF] WhatBestWayTreatWhiteCoat.pdf (63.79Kb)
    Date
    2004
    Format
    Article
    Metadata
    [+] Show full item record
    Abstract
    Evidence is conflicting regarding the risk of cardiovascular complications from white- coat hypertension. Some but not all studies show lower cardiovascular event rates for patients with white-coat hypertension compared with those with sustained hypertension (strength of recommendation [SOR]: B, cohort studies with conflicting results and methodological problems). Little information is available about the use of antihypertensive medication for white-coat hypertension. In 1 small randomized trial, the difference in stroke incidence and cardiovascular complications between active treatment and placebo did not reach statistical significance (SOR: B, based on an underpowered randomized controlled trial). Some experts recommend that patients with white-coat hypertension should be evaluated for evidence of target organ injury and monitored for the development of sustained hypertension (SOR: C, expert opinion).
    URI
    http://hdl.handle.net/10355/3209
    Part of
    Journal of family practice, 53, no. 05 (May 2004): 408+.
    Rights
    OpenAccess.
    This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.
    Collections
    • Clinical Inquiries, 2004

    Send Feedback
    hosted by University of Missouri Library Systems
     

     


    Send Feedback
    hosted by University of Missouri Library Systems